Difficulty: Medium
Average Score: 92%
Practice
A patient receiving a class I antiarrhythmic agent on a chronic basis complains of fatigue, low-grade fever, and joint pain suggestive of systemic lupus erythematosus (SLE). The patient is most likely receiving
Correct answer
B
Rationale
In this scenario, the correct answer is B) Procainamide. Procainamide is a class I antiarrhythmic agent that has been associated with drug-induced lupus erythematosus (DILE). The presentation of fatigue, low-grade fever, and joint pain in the patient suggests a possible onset of systemic lupus erythematosus (SLE) due to procainamide therapy.
Lidocaine (Option A) is not associated with causing DILE. Quinidine (Option C) is also not typically linked to drug-induced lupus. Flecainide (Option D) is a class Ic antiarrhythmic agent and is not commonly known to cause DILE.
Educationally, it is crucial for healthcare professionals to be aware of the potential adverse effects of medications, especially in the case of antiarrhythmic agents which can have significant systemic impacts. Understanding the side effect profiles of different drugs helps in making informed decisions regarding treatment plans and managing patient care effectively. Monitoring for signs and symptoms of adverse drug reactions is essential in ensuring patient safety and well-being.
Lidocaine (Option A) is not associated with causing DILE. Quinidine (Option C) is also not typically linked to drug-induced lupus. Flecainide (Option D) is a class Ic antiarrhythmic agent and is not commonly known to cause DILE.
Educationally, it is crucial for healthcare professionals to be aware of the potential adverse effects of medications, especially in the case of antiarrhythmic agents which can have significant systemic impacts. Understanding the side effect profiles of different drugs helps in making informed decisions regarding treatment plans and managing patient care effectively. Monitoring for signs and symptoms of adverse drug reactions is essential in ensuring patient safety and well-being.